TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07192432: Gene Therapy for HER-Positive Cancer (SENTRY-HER2)

Sponsor: Vironexis Biotherapeutics Inc. · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 27 pts

Competing Trials Overlap

8 Active Trials

Excess Burn Exposure

$1,727,880

Rescue Site Savings

+$1,138,830

Unlock Full NCT07192432 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07192432 Rescue Dossier →